

Lenalidomide-4-aminomethyl hydrochloride Biochemical

Lenalidomide-4-aminomethyl hydrochloride

CATALOG #
AAA228718


PRODUCT SYNONYMS

Lenalidomide-4-aminomethyl hydrochloride; Lenalidomide-4-aminomethyl hydrochloride biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	444289-05-8
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
L-Aspartic acid 13C, CAS 81201-97-0



Structure
L-Aspartic acid 13C, CAS 81201-97-0

ADDITIONAL INFORMATION

Related Product Information for Lenalidomide-4-aminomethyl hydrochloride biochemical	Lenalidomide-4-aminomethyl hydrochloride is the Lenalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Lenalidomide-4-aminomethyl hydrochloride can be connected to the ligand for protein by a linker to form PROTAC
References	- Leopold CS, et al. In vivo pharmacokinetic study for the assessment of poly(L-aspartic acid) as a drug carrier for colon-specific drug delivery. J Pharmacokinet Biopharm. 1995 Aug;23(4):397-406. - Hosoya K, et al. Blood-brain barrier produces significant efflux of L-aspartic acid but not D-aspartic acid: in vivo evidence using the brain efflux index method. J Neurochem. 1999 Sep;73(3):1206-11.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

